Arrhythmia/EP
Oct 21, 2009 11:32 EDT
Dr. Anne Curtis offers 2 cases of high-risk patients who present with shortness of breath. How are these patients diagnosed and treated?
Arrhythmia/EP
Oct 16, 2009 09:05 EDT
Rate control, rhythm control, new drugs and devices for anticoagulation -- the armamentarium of treatment options is expanding rapidly. Drs. Yancy, Cannon, and Boehmer discuss the latest treatment modalities for patients with AF.
Arrhythmia/EP
Sep 22, 2009 16:57 EDT
This review discusses risk factors of AF, the influence of AF on outcomes, and highlights recent data suggesting that secondary prevention of AF may help to reduce the burden of the arrhythmia.
Acknowledgements
CME provider: MedscapeCME.
The Advances in Atrial Fibrillation clinical theme is supported by an independent educational grant from sanofi-aventis.
button
Steering committee
The steering committee members are active in overseeing the development and direction of this educational series.

Anne B. Curtis, MD
Nicholas Danchin, MD, FESC
Keith A. A. Fox, MB, ChB
Paulus Kirchhof, MD
Gerald V. Naccarelli, MD
Carl J. Pepine, MD
Eric Prystowsky, MD
Previews
Featured CME
Resource center
Poll
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.

How do you think the results of the MADIT-CRT trial (and other studies suggesting benefits of CRT device-based therapy in earlier-stage HF patients) will affect implant CRT rates in the next 3 years?
See: MADIT-CRT: Resynchronization therapy cuts heart-failure risk in patients with only mild disease
Rates will significantly increase (> 15% increase in primary prevention ICD utilization in congestive HF patients)
Rates will moderately increase (5%-10%)
Rates will slightly increase (2%-5%)
Rates will slightly increase (2%-5%)